A patient with COVID-19 pneumonia is on high-flow nasal oxygen at 40 L/min with FiO2 0.6 (SpO2 93%). He is day 8 of illness. According to WHO Solidarity and RECOVERY trial findings, what is the optimal pharmacological treatment at this stage?
- A Remdesivir 200 mg loading + 100 mg daily × 5 days
- B Dexamethasone 6 mg/day × 10 days to reduce immunopathology ✓
- C Baricitinib (JAK inhibitor) monotherapy for cytokine storm
- D Convalescent plasma infusion for passive immunity
Explanation
The RECOVERY trial (2020, NEJM) demonstrated that dexamethasone 6 mg/day for up to 10 days significantly reduced 28-day mortality in COVID-19 patients requiring oxygen supplementation (risk ratio 0.80) and mechanical ventilation (RR 0.65), but showed no benefit (and possible harm) in patients not requiring oxygen. This patient on high-flow oxygen (day 8, inflammatory phase) represents the appropriate indication for dexamethasone. The WHO Solidarity trial confirmed no significant mortality benefit of remdesivir. Baricitinib is used as adjunct to dexamethasone in severe/critical COVID. Convalescent plasma showed no benefit in hospitalised patients in the RECOVERY trial. Immunosuppression with dexamethasone is the cornerstone for hypoxic COVID-19.
Reference: Harrison's Principles of Internal Medicine, 21st ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.